Intellia sued for patent infringement by gene editing company BlueAllele (NASDAQ:NTLA)
2024-07-08
stocknshares BlueAllele, a Minnesota-based developer of gene editing technology, has filed a lawsuit against Intellia Therapeutics (NASDAQ:NTLA) in a federal court in Delaware alleging that Intellia has infringed upon three of its patents for its bio-directional insertion template technology. BlueAllele said in a statement that Intellia has used its patentedContinue Reading